Answers are grounded in this paper and cite their sources.
The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas. Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting pituitary tumors, starting from the 1970s up to today, highlighting that normalization of PRL levels, restoration of eugonadism, and reduction of tumor mass can be achieved in the majority of patients by treatment with dopamine agonists.
No takes yet. Share an insight, caveat, or question.
Auriemma et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: